Frankfurt
01.04.26 | 08:02
0,093 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:00 | OptiBiotix Health - Partial Disposal of Shares in SkinBioTherapeutics | - | RNS | ||
| Mi | SkinBioTherapeutics - Update on the FRP Investigation | 1 | RNS | ||
| 01.04. | SkinBioTherapeutics shares suspended on delay to interim results | 1 | Sharecast | ||
| 01.04. | SkinBioTherapeutics - Holding(s) in Company | - | RNS | ||
| 01.04. | XFRA 5KW: AUSSETZUNG/SUSPENSION | 88 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSKINBIO THERAP LS-... ► Artikel lesen | |
| 01.04. | AIM - Suspension - Skinbiotherapeutics plc | 1 | RNS | ||
| 01.04. | SkinBioTherapeutics - Statement re. Suspension | 1 | RNS | ||
| SKINBIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.03. | SkinBioTherapeutics faces April trading suspension until review ends | 1 | Alliance News | ||
| 20.03. | SkinBioTherapeutics faces trading suspension amid probe | 1 | Investing.com | ||
| 20.03. | SkinBioTherapeutics: Handelsaussetzung wegen interner Untersuchung droht | 2 | Investing.com Deutsch | ||
| 20.03. | SkinBioTherapeutics: Update On Board Investigation and Interims Date | - | RNS | ||
| 09.03. | SkinBioTherapeutics adds interim CEO Rachel Parsonage to board | 2 | Alliance News | ||
| 09.03. | SkinBioTherapeutics - Appointment of the Interim CEO to the Board | - | RNS | ||
| 02.03. | AIM Market Roundup: IQE, System1, SkinBioTherapeutics | 3 | The Armchair Trader | ||
| 02.03. | SkinBioTherapeutics appoints interim CEO as investigation continues | 2 | Alliance News | ||
| 02.03. | SkinBioTherapeutics - Appointment of Interim CEO | 1 | RNS | ||
| 20.02. | IN BRIEF: SkinBioTherapeutics board member to oversee external probe | 1 | Alliance News | ||
| 20.02. | Skinbiotherapeutics brings in new audit chair, launches forensic review | 1 | Sharecast | ||
| 20.02. | UK Stock Market News: Anglo American, SEGRO, SkinBioTherapeutics | 4 | The Armchair Trader | ||
| 20.02. | SkinBioTherapeutics - Independent Investigation Appointment | - | RNS |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MAAT PHARMA | 5,840 | +1,39 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
21.04.2026 / 15:09 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,960 | 0,00 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| AVALYN PHARMA | 29,015 | 0,00 % | Avalyn Pharma Prices Upsized $300 Mln IPO At $18 Per Share | WASHINGTON (dpa-AFX) - Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price... ► Artikel lesen | |
| ALUMIS | 24,690 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 88,20 | +0,06 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ERASCA | 10,640 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,240 | 0,00 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| TANGO THERAPEUTICS | 21,530 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| EVOTEC | 5,240 | +4,70 % | Evotec tauscht CFO aus: Hinshelwood übernimmt | Evotec SE hat einen Wechsel im Finanzvorstand bekannt gegeben. Paul Hitchin scheidet zum 30. April 2026 aus persönlichen Gründen aus, die nach Angaben der Hamburger Gesellschaft nicht mit dem Unternehmen... ► Artikel lesen | |
| IMMUNOVANT | 27,150 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,470 | 0,00 % | Summit Therapeutics Inc. - 10-Q, Quarterly Report | ||
| TARSUS PHARMACEUTICALS | 63,66 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | ||
| PRAXIS PRECISION MEDICINES | 318,57 | 0,00 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals: Recursion Announces Board Transition | Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson... ► Artikel lesen |
SKINBIOTHERAPEUTICS PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,093 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SKINBIOTHERAPEUTICS PLC finden Sie auf Wallstreet Online.